Differentiation and Functional Characterization of iPSC-Derived Regulatory T Cells (Tregs)

Published on March 13, 2026
CELL_Ft image Treg case

A co-development case from Cellistic & Quell Therapeutics

Author: Cécile Augereau, PhD – Cell Therapy Innovation Director at Cellistic  

 

Abstract

Autoimmune diseases affect a substantial portion of the population and remain primarily managed through broad immunosuppression rather than restoration of immune tolerance. Regulatory T cells offer a targeted alternative by suppressing pathogenic immune responses instead of eliminating them. Because FOXP3⁺ CD4 regulatory T cells are inherently immunomodulatory, CAR-engineered Tregs are emerging as promising therapeutic candidates, yet their clinical translation is constrained by autologous manufacturing complexity and limited scalability.

Continue reading on website
Other news

Stable vs. Transient Expression: Which Is Right for Your Therapeutic?

March 10, 2026
Mammalian expression systems are invaluable tools for the production of a wide range of complex recombinant proteins, including antibodies, due to the ability of mammalian cells to promote correct post-translational modifications and folding.When it comes to expressing proteins in mammalian cells, there are two main alternatives: transient or stable production. Both methods have advantages and dis

Nadia Care Raises $12 Million to Expand Community-Centered Maternal Care Model Across the U.S.

March 16, 2026
Expansion in DC, Maryland, and Tennessee Markets on the Heels of Excellent OutcomesWASHINGTON, March 16, 2026 (GLOBE NEWSWIRE) -- Nadia Care, the maternal health company formerly known as Cayaba Care, announced a $12 million funding round to bring community-centered maternal care to more mothers across the U.S. The round was led by Valtruis and a major national payer, with participation from other